Oncology Clinical Trials and Research
Patients who qualify have access at Smilow Cancer Hospital's Greenwich Hospital Campus to national clinical trials and research focusing on the latest treatment protocols and medications.
What Are Clinical Trials?
Breast Cancer
A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) who have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy. Principal Investigator Barbara Ward, MD.
A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer. Principal Investigator Beverly Drucker, MD.
A011502: Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive Her2 Negative Breast Cancer. Principal Investigator Beverly Drucker, MD.
EA1131: A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy. Principal Investigator Beverly Drucker, MD.
SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Principal Investigator Beverly Drucker, MD.
SWOG S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy. Principal Investigator Beverly Drucker, MD.
ECOG E1Z11: A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms. Principal Investigator Beverly Drucker, MD.
SWOG S1207: Phase III Randomized Trial Evaluating the Use of Adjuvant Endocrine Therapy with One Year of Everolimus or Placebo in Patients with Hormone Receptor-Positive and Her2/neu Negative Breast Cancer. Principal Investigator Beverly Drucker, MD.
TARGIT-US: A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery. Principal Investigator Daniela Gidea-Addeo, MD.
Colon/Rectal Cancer
SWOG S0820: Phase III Trial Preventing Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer Using Eflornithine or Placebo and or Sulindac or Placebo. Principal Investigator Beverly Drucker, MD.
Lung Cancer
EA5142: A Randomized Phase III Study of Nivolumab after Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers. Principal Investigator Beverly Drucker, MD.
A1511216 ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker and Sequencing Trial for Patients with Resectable or Resected Lung Cancer. Principal Investigator Beverly Drucker, MD.
A081105: Phase III Trial of Erlotinib or Placebo in Patients with Completely Resected EGFR Mutant Non-Small Cell Lung Cancer. Principal Investigator Beverly Drucker, MD.
E4512: Phase III Trial of Crizotinib or Placebo with Early Stage Completely Resected Tumors Harboring ALK Fusion Protein in Non-Small Cell Lung Cancer Patients. Principal Investigator Beverly Drucker, MD.
ECOG E1505: Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for patients with Completely Resected Stage IB-IIIA NSCLC. Principal Investigator, Beverly Drucker, MD.
Lung Cancer Screening
I-ELCAP (International Early Lung Cancer Action Program) Lung Cancer Screening Trial Using Low Dose CT Scans. The study’s main objective is to learn whether the identification and early diagnosis of lung cancer leads to improvement in survival. For more information about the I-ELCAP study at Greenwich Hospital call 203-863-3760 or visit ielcap.org. Principal Investigator David Mullen, MD.
Urogenitary Cancer
S1605: Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. Principal Investigator Beverly Drucker MD.
Yale HIC1507016211: Detection of Arv7 in the Plasma of Men with Advanced Metastatic Castrate Resistant Prostate Cancer (MRCP). Principal Investigator Daniel Petrylak, MD.
Greenwich Hospital is a member of the national clinical research group Southwest Oncology Group (SWOG) enabling patients who qualify access to phase II and phase III clinical trials. Greenwich Hospital also participates in clinical trials initiated by the Yale Cancer Center. SWOG is sponsored by the National Cancer Institute. For more information about SWOG, visit
www.swog.org.
For more information
Contact clinical trials coordinators at 203-863-3760.
